By Chris Wack

Zentalis Pharmaceuticals Inc. said it has entered into a clinical collaboration agreement with GlaxoSmithKline PLC.

Zentalis said it will evaluate the combination of ZN-c3, an oral WEE1 inhibitor product candidate, and Zejula niraparib, GlaxoSmithKline's polymerase PARP inhibitor, in patients with advanced epithelial ovarian cancer.

Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies.

Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study, with GlaxoSmithKline providing all required doses of niraparib. Zentalis will maintain full ownership of ZN-c3.

Zentalis shares were up 21% to $45.21 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 12, 2021 08:39 ET (12:39 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Gsk